tepotinib hydrochloride

{
  "id": "MLC-T-ONC-008592",
  "term": "tepotinib hydrochloride",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with non-small cell lung cancer that has spread to other parts of the body and has a certain mutation (change) in the MET gene. It is also being studied in the treatment of other types of cancer. Tepotinib hydrochloride blocks a protein made by the MET gene, which may help keep cancer cells from growing and spreading and may kill them. It is a type of tyrosine kinase inhibitor. Also called Tepmetko.",
    "The hydrochloride salt form of tepotinib, an orally bioavailable inhibitor of MET tyrosine kinase with potential antineoplastic activity. Upon oral administration, tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR), is the product of the proto-oncogene c-Met and is overexpressed or mutated in many tumor cell types; this protein plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis."
  ],
  "synonyms": [
    "Tepmetko",
    "tepotinib hydrochloride monohydrate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tepotinib-hydrochloride/"
}